NEW YORK (GenomeWeb News) – Biosearch Technologies today said that it has licensed from the US Centers for Disease Control and Prevention the new "pdm" H1N1 signatures.
According to Biosearch, the new pdm panel has been optimized for enhanced sensitivity and specificity for H1N1 specimens. The new signatures qualitatively detect currently circulating Novel 2009 H1N1 and offer improved performance over the probe and primer sequences previously published on the World Health Organization’s website, the Novato, Calif.-based firm added.
"As licensors of CDC influenza signatures and as the inventors of BHQ (Black Hole Quencher) technology, Biosearch will provide access to 5’-Nuclease BHQ probes that meet CDC design and manufacturing specifications for PDM Novel 2009 H1N1 testing labs around the world," Marc Beal, director of corporate development at Biosearch, said in a statement.
Terms of the license were not disclosed.